Meeting Homepage
Speaker Bios
Speaker Presentations
Photo Gallery
Meeting Committee
Meeting Program:
Schedule-at-a-Glance
Add-on Seminars
Plenary Sessions
Workshops
PDS Workshops
Additional Events:
Networking Events
Tech Fair
Tours
Sponsors:
Meeting Sponsors
Sponsor Opportunities (PDF)
Miscellaneous Info:
Hotel
Weather and Dress
Registration:
Registration Info
Register |
Add-on Seminars
Add-On 1: Health Care
Add-On 2: Start-Up/ Entrepreneurship
Add-On 3: Industry/University & Government Laboratory
Transactions
Add-On 4: International
ADD-ON 1: HEALTH CARE
LES/AUTM Network's New Spring Line-up - Your Show
of Shows
8:30 a.m. – 8:45 a.m.
Welcome Remarks
8:45 a.m. – 9:15 a.m.
Keynote: “Arrested Development ” Translational Science: Bridging the Gap between Universities and VCs
- Karen Bernstein, PhD, Chairman, BioCentury
9:15 a.m. – 10:00 a.m.
“Who Wants to Be a Millionaire? ” Drexel
University’s Spin-out Model
In an effort to ensure that University technologies are commercially
developed, Drexel's Technology Commercialization Office has fostered the
development of an environment for creativity, innovation and entrepreneurship.
Notable successful licenses include Gelifex Inc, MacroArray, Immune Control
and Drakontas. Doug Adams from Drexel will describe the process and Mike
Wassil, CEO of MacroArray, will address the licensee's perspectives about
interacting with Drexel, speaking about the challenges of dealing with
early stage technologies, interacting and collaborating with the inventors,
and efforts to make the technology attractive to investors.
- Doug Adams, Director, Technology Commercialization Office, Drexel University
- Michael Wassil, CEO, MacroArray Technologies
10:00 a.m. – 10:30 a.m.
Networking/Coffee Break
10:30 a.m. – 12:00 p.m.
“Survivor” The Impact of Funding on
Licensing Deals
Catch-22: The more limited your funding options, the greater the pressure
for a licensing deal… and the greater the risk of unattractive deal
terms. In-depth knowledge of creative funding options and negotiating
strategies and tactics are critical for success. Level the playing field
with the perspectives of this panel of industry veterans, venture capitalists
and healthcare investment bankers, who will provide insights regardingthe
range of funding options as well as licensing deal terms for small emerging
companies.
Moderator:
Jack Anthony, President and CEO, Pharmix
Panelists:
- Christine Fischette, PhD, Head, Negotiations, General Medicine Business Franchise, Global Business Development and Licensing, Novartis Pharmaceuticals
- Markus Goebel, MD, PhD, Managing Director, Novartis Venture Fund
- Peter Reikes, Global Head of Health Care Investment Banking, Cowen & Co.
- Daphne Zohar, Founder and Managing Partner, PureTech Ventures
12:00 p.m. – 1:30 p.m.
Lunch
1:30 p.m. – 3:00 p.m.
“Wheel of Fortune” Negotiating Mechanism-
Based Alliances: A Treasure Trove or Pandora’s Box?
Clinically relevant compounds with defined mechanism-of-action have
long been the gold standard for pharmaceutical licensing. Recently, however,
genomic-based drug discovery and new techniques for mechanism identification
have substantially increased the "gold supply," while also posing
new and awkward challenges for licensing negotiators. How is value assessed
and shared when one company brings forward a compound while another controls
its mechanism? In addition, in a mechanism-driven collaboration, there
is enhanced potential to develop novel compounds over a wide range of
indications in very different therapeutic areas: e.g., oncology drugs
that have potential in immunology, cardiovascular drugs for metabolic
disease, and CNS drugs for cardiovascular disorders. The approaches that
have been taken to address these issues, including scalable milestones,
indication splitting and threshold payments, risk pushing a negotiation
to a level of complexity that may be a hindrance to getting the deal done.
These panel members will discuss their experiences and share their predictions
for licensing in a mechanism-based deal environment.
Moderator:
Mark Wiggins, Executive Vice President, Corporate and Business
Development, Biogen-Idec.
Panelists:
- Thomas Hofstaetter, PhD, Senior Vice President, Corporate Business Development, Wyeth
- Noel Hall, Co-Founder, President and Director, Aspreva Pharmaceuticals
- David Ghesquiere, Vice President, Business Development, OSI Pharmaceuticals
- Ronald Pepin, PhD, Senior Vice President, Business Development, Medarex
3:00 p.m. – 3:30 p.m.
Networking/Coffee Break
3:30 p.m. – 4:15 p.m.
“Let’s Make a Deal” Pharmaceutical
Litigation Outlook
The “brand v. generic wars” continue. Even state Attorneys
General Offices around the nation and the class action plaintiff’s
bar have joined the battles. Important considerations will be explored
as to how brand and generic pharmaceutical companies can (or want) to
settle cases within the context of the Hatch- Waxman Act and the MMA Act.
Ed Haug will focus not only on some of the most significant litigations
involving pharmaceuticals, but also on the current legal and business
climate for “making deals.” Issues of the day will be addressed
concerning the FTC, FDA, legislative reform and important U.S. Supreme
Court decisions.
Edgar Haug, Attorney and Partner, Frommer Lawrence & Haug &
Haug
4:15 p.m. – 5:00 p.m.
“I’ve Got a Secret” Competitive
Intelligence and How to Get It
In this session, you will learn about the role of competitive intelligence
and its contribution to the licensing process. We will focus also on how
companies can create and maximize competitive intelligence to help them
to make better and faster decisions.
Daniel Pascheles, Vice President, Corporate Competitive Intelligence, Merck & Co.
[back to top]
ADD-ON 2: START-UP/ ENTREPRENEURSHIP
Keys to Successful New Ventures
8:15 a.m. – 8:30 a.m.
Welcome Remarks
8:30 a.m. – 10:00 a.m.
Taking Early Stage Technology to Market
This session will discuss how to create and successfully launch companies
based on university discoveries. In particular: how opportunities are
recognized and evaluated; what the steps and resources are that help optimize
the success of a start-up based on such early stage technology; how markets
are identified and market players brought into the picture early on; and
what capitalization options are available. These points will be illustrated
with case studies of companies that are or are becoming successful.
- Daryl Boudreaux, Founder, NanoHoldings, LLC and
VP for Professional Development, AUTM
- Ted Goldman, Senior Consultant, Martec Group
- Michael Janse, Associate, ARCH Venture Partners
10:00 a.m. – 10:30 a.m.
Networking/Coffee Break
10:30 a.m. – 12:00 p.m.
Improving the Probability of Success for Spin-offs
and Start-ups
This session will discuss guiding principles for building better companies,
as well as sharing illustrative examples of fatal errors. Even though
each new venture is unique, there are predictable challenges and pitfalls
for growing technology companies that can be avoided or minimized with
proper foresight during license negotiations.
- Christopher Wright, Shareholder, McCausland, Keen
& Buckman
- Robert B. McGrath, former Interim Director of Technology
Licensing, Center of Technology Transfer, University of Pennsylvania
- John S. Zawad, former Vice President, Sanofi-Adventis
Capital
12:00 p.m. – 1:30 p.m.
Lunch
1:30 p.m. – 3:00 p.m.
Translational Science Bridging the Gap between Universities
and VCs
This session will discuss the opportunities and challenges faced by
university spin-offs seeking angel financing. Angel investors are typically
wealthy individuals looking to invest large sums of money in young businesses,
often those based on emerging technologies. Angels (as opposed to venture
capitalists) usually invest very early in the life cycle of a spin-off/start-up
company. In addition to offering significant capital to launch business
entities, many angel investors also offer their business expertise and
actively participate in the management, operation, and marketing of the
business.
- Peter Durant, Partner, Nixon Peabody, LLP
- Dennis DeLeo, President, Trillium Capital Partners
3:00 p.m. – 3:30 p.m.
Networking/Coffee Break
3:30 p.m. - 5:00 p.m.
The OVALS Initiative: One Region's Approach to "Building
Bridges to Collaboration"
Getting University, Industry and Government entities to play well together
is never an easy task, but OVALS (The Ohio Valley Affiliates for Life
Sciences) has blazed the pathway to do so - crossing the physical boundaries
of a river and state lines, and the psychological boundaries of Federal,
State, Academic and Corporate culture. OVALS is an initiative that has
demonstrated that egos CAN be set aside to become a team and allow regions
to best position themselves as a Life Science hub.
Moderator:
- James Zanewicz, Director, University of Louisville
Office of Technology Transfer
- Dorothy Air, Associate Senior Vice President for
Entrepreneurial Affairs, University of Cincinnati
- Scott Hall, Air Force Research Laboratories
[back to top]
ADD-ON 3: INDUSTRY/UNIVERSITY & GOVERNMENT LABORATORY
TRANSACTIONS
Best Practices at the Industry/Academic Interface
8:30 a.m. – 8:45 a.m.
Welcome Remarks
8:45 a.m. – 10:00 a.m.
Strategies for Developing and Licensing IP in View
of Recent Supreme Court Cases and Pending Federal Legislation
This session will discuss strategies for developing and licensing IP
in view of the recent Supreme Court cases, including Merck v. Integra;
Laboratory Corp. of America v. Metabolite; and eBay v. MercExchange; as
well as federal legislation, including the Patent Reform Act and the CREATE
Act. Additionally, this session will provide guidance about best practices
for strategic alliances created by contract, with an emphasis on sponsored
research agreements, clinical trial agreements, material transfer agreements,
and consulting agreements.
- Mark Bloom, Legal Consultant, Business Success Strategists,
LLC, and former Chief IP Counsel, The Cleveland Clinic Foundation
- Gunnar Leinberg, Partner, Nixon Peabody, LLP
10:00 a.m. – 10:30 a.m.
Networking/Coffee Break
10:30 a.m. – 12:00 p.m. Sponsored
Research: IP Demands in Deals between Universities
and Industry
This session will focus on the intellectual property interests of universities
and industry in negotiating and administering sponsored research agreements.
Topics will include the extent to which intellectual property rights are
retained by the university and granted to the research sponsor; sharing
licensing revenues; the right to the free publication of results; and
universities' interests in making inventions available under conditions
that will promote their effective development and utilization in the public
interest.
- Thomas Meagher, Partner, Duane Morris, LLP
- Scott Bluni, Senior Patent Counsel, Boston Scientific
Corporation
- John Ritter, Director, Patents & Licensing,
Princeton University
12:00 p.m. – 1:30 p.m.
Lunch
1:30 p.m. – 3:00 p.m.
“Entrepreneurial University”: Building
a Winning Program that Fosters Start-Up Creation and Success
A panel of experts from the investment community, academia, and industry,
will lead a thought-provoking discussion of the challenges, and success/failure
factors involved in creating an “entrepreneurial university.”
Indeed, as repositories of innovations and knowledge, research institutions
form a vibrant innovation pool which investors may tap to find the “golden
grail.” Entrepreneurship does not stop at the company creation stage,
though, and start-ups need to make their first steps in a supportive environment
shaped in part by the parent university. However, entrepreneurship is
not always a natural fit in the academic/non-profit culture. Thus, there
is a clear need for fostering a university entrepreneurial culture suitable
to maximize successful start-up creation and growth. This discussion will
address needs/expectations, infrastructure models, and early start-up/
university relations and is expected to provide valuable insight about
strategies to consider
when creating/ managing a university entrepreneurial activity.
- Cathy Renault, Program Manager, Technology-based
Economic Development, RTI International
- Isabelle M. Gorrillot, Sc.D., Director, Technology
Transfer, Wright State University
- Douglas Jamison, President and Chief Operation
Officer, Harris & Harris Group
- Timothy Weihs, Founder, Reactive Nanotechnologies
- Christine Jansen, Ph.D., President, Jansen and Associates
3:00 p.m. – 3:30 p.m.
Networking/Coffee Break
3:30 p.m. – 5:00 p.m.
Commercialization Analyst Interns: A Programmatic
Approach to Screening New Technology
This session will discuss how graduate student interns can help university
technology transfer offices screen new disclosures and in the process,
gain valuable training and experience. For the last four years the Office
of Technology Management (OTM) at the University of Illinois at Urbana-Champaign
has had a system in place that utilizes graduate student interns for screening
as well as in other intern initiatives that have yielded strong results.
Through an intensive three-week training effort they are taught the OTM’s
screening methodology to become adept at searching for background IP,
assessing where a technology fits in its potential market, and with the
Technology Manager making recommendations on whether and how to proceed
with commercialization.
- Lesley Millar, Director of the Office of Technology Management, University of Illinois at Urbana-Champaign
- Joe Bradley, Office of Technology Management, University
of Illinois at Urbana-Champaign
[back to top]
ADD-ON 4: INTERNATIONAL
Strategies for Licensing Success in Europe and East
Asia
1:30 p.m. - 1:40 p.m.
Welcome Remarks
1:40 p.m. - 2:40 p.m.
A Business Perspective on Connecting Licensees between
the United States and Japanese and Chinese Companies
Experts in the field will discuss the overall process of forming a licensing
arrangement starting from connecting with potential licensees through
to growing the connection into a long-term relationship with a focus on
connecting in light of cultural differences. Additionally, this session
will discuss issues in identifying potential licensees, approaching perspective
licensees, negotiating license agreements, and developing the connection.
- Heidi Ames, President, Myland USA
- Rochelle Kopp, Managing Principal, Japan Intercultural
Consulting
2:40 p.m. - 3:00 p.m.
Networking/Coffee Break
3:00 p.m. – 4:00 p.m.
Legal Issues Impacting License Negotiations in Japan
and China
This session will discuss negotiating licenses and maintaining a positive
connection with Japanese and Chinese companies.
- Joel Lutzker, Partner, Schulte Roth & Zabel,
LLP
- Taro Yaguchi, Partner, Omori & Yaguchi
4:00 p.m. – 5:00 p.m.
Legal Issues Impacting Licensing Negotiations in
Europe.
This session will discuss negotiating licenses and maintaining a positive
connection with European companies.
- Heinz Goddar, Partner, Boehmert & Boehmert
- Ray VanDyke, Partner, Nixon Peabody LLP
[back to top] |
